Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zevalin Completes Transition To ASP-Based Reimbursement In OPPS

Executive Summary

Spectrum Pharmaceuticals' radiopharmaceutical Zevalin (ibritumomab tiuxetan) will be reimbursed like other Medicare Part B drugs administered in the hospital outpatient setting, according to the final outpatient prospective payment update for 2010
Advertisement

Related Content

Cancer Drug Zevalin May Finally Thrive Under Spectrum
Cancer Drug Zevalin May Finally Thrive Under Spectrum
CMS Proposes Compendia Publish All Materials Related To Listing Decision
Medicare Holds Hospital Outpatient Payment For Drugs At ASP+4% For 2010
CTI Bags Cash, Turns Its Back On Zevalin

Topics

Advertisement
UsernamePublicRestriction

Register

PS051656

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel